Suchergebnisse - "Daratumumab"

PubPharm (1.488)

61

Daratumumab for patients with myeloma with early or late relapse after initial therapy : subgroup analysis of CASTOR and POLLUX

enthalten in: Blood advances | 2024

von Spencer, A. | Moreau, P. | Mateos, M. | +17

62

Treatment of Refractory p53 Mutation Large B-cell Lymphoma with Daratumumab and Venetoclax Followed by CAR-T Cell Therapy : Case Report and Animal Study

enthalten in: Recent patents on anti-cancer drug discovery | 2024

von Gong, D. | Gu, J. | Zhou, K. | +1

63

Immune profiling of patients with extranodal natural killer/T cell lymphoma treated with daratumumab

enthalten in: Annals of hematology | 2024

von Qing, M. | Zhou, T. | Perova, T. | +19

64

Successful Treatment of Systemic Light Chain Amyloidosis with Liver Involvement using Low-Frequency Daratumumab : A Case Report

enthalten in: The American journal of case reports | 2024

von Meng, X. | He, J. | Cheng, F. | +6

65

Complete Remission in a TEMPI Syndrome Treated with a Daratumumab, Lenalidomide, and Dexamethasone-Based Regimen : A Case Report

enthalten in: Case reports in oncology | 2024

von Sansen, P. | Montfort, L. | Nanquette, A. | +2

66

Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma : a systemic review

enthalten in: Frontiers in oncology | 2024

von Tang, W. | Zhang, L. | Zheng, Y. | +2

67

Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma : TAURUS Chart Review Study

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Gordan, L. | Tan, C. | Vescio, R. | +12

68

A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients : a report from the Triveneto Myeloma Working Group

enthalten in: Annals of hematology | 2024

von Barilà, G. | Quaglia, F. | Furlan, A. | +21

69

Identifying clinical response to daratumumab therapy in relapsed/refractory multiple myeloma using a patient‐derived in vitro model

in: eJHaem | 2024

von Niels vanNieuwenhuijzen | Marta Cuenca | Leonie Abbink | +3

70

Complete Remission in a TEMPI Syndrome Treated with a Daratumumab, Lenalidomide, and Dexamethasone-Based Regimen: A Case Report

in: Case Reports in Oncology | 2024

von Pierre-Yves Sansen | Luc Montfort | Anne Nanquette | +2